sibeprenlimab

News

Otsuka joins IgAN market with Voyxact approval in US

Otsuka has claimed FDA approval for its IgAN therapy Voyxact, joining an increasingly crowded market and beating rival Vera Therapeutics to the punch.

News

Otsuka, Vera stake their claims to IgAN treatment

Otsuka and Vera both have new phase 3 data on drugs for kidney disease IgA nephropathy, but can they make a mark in an increasingly crowded market?

News

Otsuka eyes early filing of IgAN drug after phase 3 readout

Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial.

Otsuka joins IgAN market with Voyxact approval in US

Otsuka, Vera stake their claims to IgAN treatment

Otsuka eyes early filing of IgAN drug after phase 3 readout

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Editor's Picks